Cargando…

Selective targeting of MYC mRNA by stabilized antisense oligonucleotides

MYC is a prolific proto-oncogene driving the malignant behaviors of numerous common cancers, yet potent and selective cell-permeable inhibitors of MYC remain elusive. In order to ultimately realize the goal of therapeutic MYC inhibition in cancer, we have initiated discovery chemistry efforts aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gill, Taylor, Wang, Haichuan, Bandaru, Raj, Lawlor, Matthew, Lu, Chenyue, Nieman, Linda T., Tao, Junyan, Zhang, Yixian, Anderson, Daniel G., Ting, David T., Chen, Xin, Bradner, James E., Ott, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627489/ https://www.ncbi.nlm.nih.gov/pubmed/34650218 http://dx.doi.org/10.1038/s41388-021-02053-4

Ejemplares similares

Antisense-oligonucleotide-directed inhibition of nonsense-mediated mRNA decay
por: Nomakuchi, Tomoki T., et al.
Publicado: (2015)

Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
por: Ham, Kristin A., et al.
Publicado: (2021)

Targeting 3′ and 5′ untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression
por: Li, Yanjie, et al.
Publicado: (2021)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Selection of antisense oligonucleotides based on multiple predicted target mRNA structures
por: Bo, Xiaochen, et al.
Publicado: (2006)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Small antisense oligonucleotides against G-quadruplexes: specific mRNA translational switches
por: Rouleau, Samuel G., et al.
Publicado: (2015)

mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
por: Liang, Xue-hai, et al.
Publicado: (2019)

Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm
por: Grabowska-Pyrzewicz, Wioleta, et al.
Publicado: (2021)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides
por: Anderson, Brian R., et al.
Publicado: (2020)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement
por: Batista-Duharte, Alexander, et al.
Publicado: (2020)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021)

Inactivating Gene Expression with Antisense Modified Oligonucleotides
por: Altman, Sidney, et al.
Publicado: (2021)

Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021)

Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)

Antisense oligonucleotide therapy for KCNT1 encephalopathy
por: Burbano, Lisseth Estefania, et al.
Publicado: (2022)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
por: Zhang, Y, et al.
Publicado: (2011)

Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB
por: Khoo, Bernard, et al.
Publicado: (2007)

Targeting TGFβ Signaling to Address Fibrosis Using Antisense Oligonucleotides
por: March, James T., et al.
Publicado: (2018)

Solid-Phase Synthesis of Boranophosphate/Phosphorothioate/Phosphate Chimeric Oligonucleotides and Their Potential as Antisense Oligonucleotides
por: Takahashi, Yuhei, et al.
Publicado: (2021)

AOBase: a database for antisense oligonucleotides selection and design
por: Bo, Xiaochen, et al.
Publicado: (2006)

Morpholino antisense oligonucleotides: tools for investigating vertebrate development
por: Corey, David R, et al.
Publicado: (2001)

Intracerebral Infusion of Antisense Oligonucleotides Into Prion-infected Mice
por: Nazor Friberg, Karah, et al.
Publicado: (2012)

New treatments for myasthenia: a focus on antisense oligonucleotides
por: Angelini, Corrado, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bnhkabh6lj9rha86t6oe6s2cd2